#United States #South San Francisco #Rigel Pharmaceuticals #R289 #mIDH1 AML

Rigel Pharmaceuticals to Showcase Cutting-Edge Research at ASH 2025

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a notable player in biotechnology focused on hematological disorders and cancer treatment, has announced this year's presentations scheduled for the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The event will occur from December 6 to 9, 2025, in Orlando, Florida. Rigel will present significant findings from their ongoing clinical trials involving two potentially groundbreaking treatments: R289 and REZLIDHIA®.

Key Oral Presentation on R289

On December 7, 2025, Rigel will deliver an oral presentation detailing updated data from a Phase 1b study of R289, a dual IRAK1/4 inhibitor designed for patients suffering from relapsed or refractory lower-risk Myelodysplastic Syndromes (MDS). This study aims to address the critical need for additional therapies for transfusion-dependent patients, providing an innovative approach given the limitations of existing treatments.

Dr. Guillermo Garcia-Manero, the presenter of the study, will discuss how R289 has been well tolerated among patients, reporting common side effects such as diarrhea, fatigue, and liver enzyme increases. The preliminary results reveal that a subset of patients have shown significant improvements regarding red blood cell transfusion independence, essential for their quality of life. As of the cutoff data on July 15, 2025, patients receiving the highest dosages exhibited a 31% chance of gaining long-term transfusion independence, highlighting R289’s potential to transform treatment approaches for MDS.

Insights From Four Poster Presentations

In addition to the main presentation, Rigel will showcase four poster presentations focusing on new data related to REZLIDHIA®, which targets patients with relapsed or refractory mutated isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). Each report delves into various aspects of clinical outcomes following treatment with olutasidenib, emphasizing how it meets a crucial unmet need for effective therapies in this high-risk patient population.

Summary of Poster Topics:

1. Clinical Characteristics in mIDH1 AML: The effectiveness of olutasidenib was analyzed in patients maintaining stable disease after two treatment cycles, revealing a robust response rate among those treated.
2. Real-World Data Analysis: A retrospective study examined treatment patterns and outcomes for mIDH1 AML patients previously treated with the commonly used drug venetoclax, which showcased a 50% response rate in patients subsequently treated with olutasidenib.
3. Hematologic Improvements Over Time: Evaluating the time to response in AML patients, critical advancements in hemoglobin levels were observed, supporting the continuation of therapy beyond initial cycles.
4. Monotherapy Outcomes in Prior Intensive Chemotherapy Patients: Outcomes demonstrated significant response rates among patients undergoing olutasidenib monotherapy who previously received intensive chemotherapy, providing evidence for its durability and safety profile.

Commitment to Unmet Needs

Dr. Lisa Rojkjaer, Chief Medical Officer of Rigel, expressed enthusiasm about the opportunity to present at ASH, emphasizing the importance of addressing significant treatment voids for patients with lower-risk MDS and aggressive forms of AML. Rigel aims to push the boundaries of therapy for these conditions, particularly for those who often face multiple treatment lines without favorable outcomes.

Conclusion

With the forthcoming presentations, Rigel Pharmaceuticals is poised to make an impactful contribution to the understanding and treatment of hematologic malignancies, aiming for pathways that improve patient outcomes significantly. The presentations can be accessed online via the ASH website, providing further insight into these groundbreaking therapies. Rigel’s commitment to innovation in oncology represents a beacon of hope for patients facing serious health challenges due to MDS and AML.

Stay tuned for more updates as Rigel shares its research findings, contributing to the fight against leukemia and related diseases at the forefront of clinical research.

For more details on the presentations and Rigel’s portfolio, visit Rigel Pharmaceuticals.